TW201019962A - Ligands that have binding specificity for DC-SIGN - Google Patents

Ligands that have binding specificity for DC-SIGN Download PDF

Info

Publication number
TW201019962A
TW201019962A TW098135298A TW98135298A TW201019962A TW 201019962 A TW201019962 A TW 201019962A TW 098135298 A TW098135298 A TW 098135298A TW 98135298 A TW98135298 A TW 98135298A TW 201019962 A TW201019962 A TW 201019962A
Authority
TW
Taiwan
Prior art keywords
lip1
seq
amino acid
ser
sign
Prior art date
Application number
TW098135298A
Other languages
English (en)
Chinese (zh)
Inventor
Wildt Rudolf Maria De
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of TW201019962A publication Critical patent/TW201019962A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
TW098135298A 2008-10-21 2009-10-19 Ligands that have binding specificity for DC-SIGN TW201019962A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10708508P 2008-10-21 2008-10-21

Publications (1)

Publication Number Publication Date
TW201019962A true TW201019962A (en) 2010-06-01

Family

ID=42062429

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098135298A TW201019962A (en) 2008-10-21 2009-10-19 Ligands that have binding specificity for DC-SIGN

Country Status (16)

Country Link
US (1) US20110257373A1 (enExample)
EP (1) EP2356149A2 (enExample)
JP (1) JP2012506237A (enExample)
KR (1) KR20110071139A (enExample)
CN (1) CN102257009A (enExample)
AR (1) AR073905A1 (enExample)
AU (1) AU2009306424A1 (enExample)
BR (1) BRPI0919714A2 (enExample)
CA (1) CA2740856A1 (enExample)
EA (1) EA201100488A1 (enExample)
IL (1) IL212086A0 (enExample)
MX (1) MX2011004244A (enExample)
TW (1) TW201019962A (enExample)
UY (1) UY32189A (enExample)
WO (1) WO2010046337A2 (enExample)
ZA (1) ZA201102763B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004245A (es) * 2008-10-21 2011-09-06 Domantis Ltd Composicion para dirigirse a las celulas dendriticas.
US9481724B2 (en) * 2011-12-19 2016-11-01 The Rockefeller University hDC-sign binding peptides
WO2023028593A2 (en) * 2021-08-27 2023-03-02 University Of Georgia Research Foundation, Inc. Targeted nanoparticles and their uses related to infectious disease
CN118184795B (zh) * 2022-12-13 2025-03-21 成都维瑾柏鳌生物医药科技有限公司 抗hiv-1的重组蛋白及其应用
CN120591214A (zh) * 2025-07-02 2025-09-05 山东第一医科大学第二附属医院 一种过表达dc-sign基因的重组arh77细胞系及其构建方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0598108A1 (en) * 1992-06-05 1994-05-25 Dade Produktions AG Rabbit single domain antibody and use thereof
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
JP4889493B2 (ja) * 2003-05-14 2012-03-07 ドマンティス リミテッド ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
JP5087274B2 (ja) * 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
WO2005018610A1 (en) * 2003-08-21 2005-03-03 Lipotek Pty Ltd In vivo targeting of dendritic cells
US8921528B2 (en) * 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
MX2007006593A (es) * 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
JP5185624B2 (ja) * 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
JP2008533115A (ja) * 2005-03-18 2008-08-21 ドマンティス リミテッド カンジダ抗原に対する抗体
EP1966242A1 (en) * 2005-12-06 2008-09-10 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
US20100021473A1 (en) * 2005-12-06 2010-01-28 Domantis Limited Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
BRPI0710572A2 (pt) * 2006-01-24 2013-01-08 Domantis Limited ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas
WO2008039432A1 (en) * 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
EP2077863A4 (en) * 2006-10-31 2010-10-06 Domantis Ltd intrabodies
CN101182539A (zh) * 2007-11-06 2008-05-21 浙江大学 Dc-sign启动子荧光素酶报告质粒的构建方法

Also Published As

Publication number Publication date
JP2012506237A (ja) 2012-03-15
CA2740856A1 (en) 2010-04-29
KR20110071139A (ko) 2011-06-28
UY32189A (es) 2010-05-31
EA201100488A1 (ru) 2011-12-30
ZA201102763B (en) 2012-09-26
AU2009306424A1 (en) 2010-04-29
MX2011004244A (es) 2011-05-25
US20110257373A1 (en) 2011-10-20
IL212086A0 (en) 2011-06-30
CN102257009A (zh) 2011-11-23
WO2010046337A3 (en) 2010-07-01
AR073905A1 (es) 2010-12-09
WO2010046337A2 (en) 2010-04-29
EP2356149A2 (en) 2011-08-17
BRPI0919714A2 (pt) 2015-12-08

Similar Documents

Publication Publication Date Title
KR101791372B1 (ko) Ｃｄ２８ 결합에 대해 １가인 조성물 및 사용 방법
EP2576618B1 (en) Antibodies to human gdf8
KR102658637B1 (ko) T 세포 관여 항체 구축물을 포함하는 저 pH 약제학적 조성물
TWI373343B (en) Antibodies that bind human interleukin-18 and methods of making and using
CN101589062B (zh) 与胰高血糖素受体抗体相关的组合物和方法
CN114507284B (zh) 抗tigit的抗体、其制备方法和应用
RU2770209C2 (ru) Терапевтические антитела против лиганда cd40
AU2020213579B2 (en) Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
TW201632559A (zh) 結合ｃｄ１３７之抗體治療劑
KR102967396B1 (ko) Gipr 항체 및 이와 glp-1의 융합 단백질, 및 그의 약학 조성물 및 적용
KR20180037950A (ko) 메소텔린 및 cd3에 결합하는 이중특이적 항체 작제물
WO2015085847A1 (zh) Pd-1抗体、其抗原结合片段及其医药用途
TW201008581A (en) Compositions monovalent for CD28 binding and methods of use
TW202233674A (zh) 用於調節δγ鏈介導之免疫的組成物及方法
CN112521501A (zh) Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
WO2022199590A1 (zh) 一种靶向bcma的纳米抗体及其应用
KR20120101417A (ko) 안정한 항?ｔｎｆｒ1 폴리펩티드，항체 가변 도메인 및 길항제
TW201143789A (en) Antigen binding proteins
CN114685666A (zh) 抗间皮素纳米抗体及其应用
WO2024094076A1 (zh) 一种gipr结合蛋白及其应用
KR20110071139A (ko) Ｄｃ­ｓｉｇｎ에 대한 결합 특이성을 갖는 리간드
KR20230104229A (ko) Cd3에 결합하는 폴리펩티드 구축물
CN110343178A (zh) 抗人lag-3单克隆抗体及其应用
WO2023279803A1 (zh) Rbv的蛋白结合分子及其用途
HK40123789A (en) Optimized anti-tl1a antibodies